Anti-CD19 chimeric antigen receptor T-cell therapy for relapsed or refractory Philadelphia chromosome-positive B cell acute lymphoblastic leukemia: a multicenter retrospective study - PubMed
8 hours ago
- #CAR T-cell therapy
- #hematologic malignancies
- #acute lymphoblastic leukemia
- CD19 CAR T-cell therapy shows high efficacy in relapsed/refractory Ph+ B-ALL, with an 87.1% complete remission rate.
- Long-term outcomes include a median overall survival of 20.8 months and leukemia-free survival of 8.1 months.
- Better performance status and absence of adverse genetic features correlate with improved survival outcomes.
- Consolidative allo-HSCT post-CAR T therapy did not independently improve survival outcomes.
- Safety profile was manageable, with grade ≥3 cytokine release syndrome in 14.0% and neurotoxicity in 2.2% of patients.
- Hematologic adverse events, primarily cytopenias, were common but manageable with supportive care.